Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.13), Zacks reports.
Corbus Pharmaceuticals Stock Down 1.5 %
CRBP traded down $0.10 on Friday, hitting $6.55. 24,169 shares of the company traded hands, compared to its average volume of 360,073. The company has a 50 day moving average of $6.33 and a 200-day moving average of $10.93. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $61.90. The stock has a market capitalization of $80.12 million, a PE ratio of -1.40 and a beta of 3.19.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on CRBP. Oppenheimer cut their price objective on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a report on Wednesday. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a report on Thursday, March 6th. Jefferies Financial Group decreased their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. B. Riley reissued a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Finally, HC Wainwright dropped their price objective on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $50.88.
Check Out Our Latest Stock Report on Corbus Pharmaceuticals
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Recommended Stories
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
